Pathogenic variants in the BRCA 1/2 genes represent a significant risk factor for cancer development, with a lifetime cumulative risk up to 72–69% for breast cancer and 44–17% for ovarian cancer for BRCA1 and BRCA2 pathogenic variant carriers, respectively [1]. This evidence concerns the gene BRCA2 and breast carcinoma.